NCT05055635 (ReRad III) is a Phase 2 clinical trial of Pencil beam proton therapy in Anal Cancer, sponsored by University of Aarhus.

Who is sponsoring NCT05055635?

NCT05055635 is sponsored by University of Aarhus.

What drugs are being tested in NCT05055635?

Interventions in NCT05055635: Pencil beam proton therapy.

What condition does NCT05055635 study?

NCT05055635 studies Anal Cancer, Recurrent Anal Cancer.

Is NCT05055635 still recruiting?

NCT05055635 is currently recruiting now. Last updated 24 September 2021.

Last reviewed 2021-09-24 · How we verify

NCT05055635: ReRad III

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy (DACG 5)

Recruiting now Phase 2 Last updated 24 September 2021

What this trial tests

Phase 2 trial testing Pencil beam proton therapy in Anal Cancer in 55 participants. Currently enrolling.

Timeline

7 July 2021

Primary endpoint
6 July 2027

6 July 2030

Quick facts

Lead sponsor	University of Aarhus
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	55
Start date	7 July 2021
Primary completion	6 July 2027
Estimated completion	6 July 2030
Sites	1 location across Denmark

Drugs / interventions tested

Pencil beam proton therapy

Conditions studied

Anal Cancer — all drugs for Anal Cancer →
Recurrent Anal Cancer — all drugs for Recurrent Anal Cancer →

Sponsor

University of Aarhus

Who can join

18 and older, any sex, with Anal Cancer or Recurrent Anal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This protocol aims to determine toxicity and efficacy of re-irradiation for patients with recurrences from anal cancers with dose-escalated pencil beam proton therapy either pre-operative for marginally resectable recurrences or as a definitive treatment strategy (un-resectable, operation declined etc.). The over-all aim is to improve local tumor control with acceptable side effects.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Recent Advances in the Management of Anal Cancer.
Upadhyay L, Hartzell M, Parikh AR, Strickland MR, et al · · 2023 · cited 7× · PMID 38063578 · DOI 10.3390/healthcare11233010
PTCOG Gastrointestinal Subcommittee Lower Gastrointestinal Tract Malignancies Consensus Statement.
Isabelle Choi J, Wojcieszynski A, Amos RA, Giap H, et al · · 2024 · cited 3× · PMID 38757077 · DOI 10.1016/j.ijpt.2024.100019

Verify or expand the search:

Other recruiting trials for Anal Cancer

Currently open trials in the same condition.

NCT07192055 — Self-sampling to Optimize Anal Lesion Outcomes · NA · recruiting
NCT07296237 — Beyond Survival: Addressing Gynecological and Sexual Health in Women After Radiotherapy for Anal Cancer · recruiting
NCT07124000 — DESTINY-PANTUMOUR04 · recruiting
NCT05639972 — E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers · Phase 1, PHASE2 · recruiting
NCT06670495 — HPV Genotype Attribution and Disease Burden of Anal Cancer in China · recruiting

Other University of Aarhus trials

Trials by the same sponsor.

NCT07209540 — European LUpuS Inception-Cohort Developing initiATivE · not yet recruiting
NCT07317401 — Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalo · NA · not yet recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
NCT07528339 — Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) · not yet recruiting
NCT07451028 — Effect of an Oral Neuromuscular Training Device on Dysphagia · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05055635 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Aarhus
Last refreshed: 24 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05055635.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing